Cathie Wood’s Ark Funds Built Up Big Stakes in Crispr Stock. Now It’s Tumbling.


This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit

  • Order Reprints
  • Print Article

Crispr Therapeutics stock was tumbling Wednesday after the results of an experimental treatment from the gene-based medicine specialist underwhelmed investors. 

That is bad news for high-profile investor Cathie Wood, whose Ark Investment Management recently bought shares in the biotech company for two of its actively managed exchange-traded funds (ETFs).